ViewRay Inc. VRAY

NAS: VRAY | ISIN: US92672L1070   4/04/2024
0,025 USD (0,00%)
(0,00%)   4/04/2024

21 juli 2023 · ViewRay® Announces Commencement of Nasdaq Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Markets · Persbericht

17 juli 2023 · ViewRay® Files Voluntary Chapter 11 Petitions · Persbericht

13 juni 2023 · VA Oklahoma City Healthcare System Chooses ViewRay's MRIdian® MRI-Guided Radiation Therapy System · Persbericht

12 mei 2023 · ViewRay's MRIdian® to be Featured at Leading European Radiation Oncology Meeting · Persbericht

10 mei 2023 · ViewRay Announces First Quarter 2023 Results · Persbericht

9 mei 2023 · ViewRay Announces Conference Call for First Quarter 2023 Financial Results to be Held After Market on May 10, 2023 · Persbericht

13 april 2023 · ViewRay Announces Preliminary First Quarter 2023 Results and Updated Fiscal Year 2023 Financial Guidance; Company to Explore Strategic Alternatives to Maximize Shareholder Value · Persbericht

12 april 2023 · ViewRay Announces Conference Call for Preliminary First Quarter 2023 Financial Results to be held Pre-Market opening on April 13, 2023 · Persbericht

7 maart 2023 · Military University Hospital Prague Selects ViewRay's MRIdian® MRI-Guided Radiation Therapy System to Treat Cancer Patients · Persbericht

2 maart 2023 · Siteman Cancer Center at Washington University Treats 2,000th Patient with MRIdian® MRI-Guided Radiation Therapy · Persbericht

27 februari 2023 · ViewRay Announces Fourth Quarter and Full Year 2022 Results · Persbericht

31 januari 2023 · ViewRay Announces Conference Call for Fourth Quarter 2022 Financial Results to be Held After Market on February 27, 2023 · Persbericht

20 januari 2023 · ViewRay Enters into Cooperation Agreement with Hudson Executive Capital · Persbericht

12 januari 2023 · Findings Published in JAMA Oncology Demonstrate Superiority of MRIdian® MRI-Guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer · Persbericht

9 januari 2023 · ViewRay Announces Preliminary Fourth Quarter and Full Year 2022 Results; appoints William P. "Bill" Burke as Chief Financial Officer · Persbericht

5 januari 2023 · Chindex Medical Acquires 10 ViewRay MRIdian® Systems for Advanced Cancer Treatment · Persbericht

5 januari 2023 · University Hospitals in Cleveland Enters into Master Purchase Agreement with ViewRay for Multiple MRIdian® Systems · Persbericht

14 november 2022 · ViewRay Expands Access to Non-Dilutive Capital With New Debt Facility · Persbericht

14 november 2022 · ViewRay® to Participate in the 34th Annual Piper Sandler Healthcare Conference · Persbericht

10 november 2022 · ViewRay® to Present at the Stifel 2022 Healthcare Conference · Persbericht

Mijn selecties